Navigation Links
HEI, Inc. Initiates Delisting and Deregistration of Its Shares on NASDAQ
Date:12/7/2007

MINNEAPOLIS, Dec. 7 /PRNewswire-FirstCall/ -- HEI, Inc. (Nasdaq: HEII) (http://www.heii.com) announced today that it has voluntarily initiated the process of delisting its common stock from NASDAQ Capital Market and withdrawing its common stock from registration. The Company provided notice to the exchange on December 6, 2007 of its intent to withdraw its common stock from listing and registration on NASDAQ Capital Market, and anticipates that the last day of trading on the NASDAQ Capital Market will be Friday, December 14, 2007.

The Company plans to file a Form 25 with the Securities and Exchange Commission on December 17, 2007 to provide notice of its intention to withdraw its common stock from listing and registration under Section 12(d) of the Securities Act of 1933, as amended. The Company expects that the delisting will be effective 10 days after filing and the withdrawal of registration effective 90 days after filing. As a result of this filing, HEI's obligation to file certain reports and forms with the SEC, including Forms 10-K, 10-Q and 8-K, will be suspended on the effective date of delisting.

The Company believes that while the liquidity for its common stock may be reduced, the administrative and other economies and savings associated with delisting and deregistration are in the best interest of its shareholders. In addition, the Company believes that it would not be able to maintain NASDAQ listing for a number of reasons.

As a result of delisting and deregistration, the Company's securities will no longer be eligible for quotation on NASDAQ; however, the Company's securities may be eligible for quotation on the Pink Sheets (

SOURCE HEI, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program
2. Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership
3. Vista Partners Initiates Coverage on Raptor Pharmaceuticals Corp.
4. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
5. GenPrime Initiates External Clinical Trials of its Bacterial Contamination Test for Rapid Detection of Bacteria in Platelets
6. U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
7. Harbinger Research Initiates Coverage on HearAtLast
8. Wyeth Consumer Healthcare Initiates Voluntary Recall and Replacement Program for Several Robitussin Products and Childrens Dimetapp Cold & Chest Congestion
9. MAP Pharmaceuticals Initiates Phase 2a Clinical Trial of Combination Therapy in Adult Patients with Asthma
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2VA Announces 2426 Million Construction Contract for Palo Alto 51841 1Vein Removal Method Linked to Bypass Results 51837 1Vein Removal Method Linked to Bypass Results 51837 2Vein Removal Method Linked to Bypass Results 51837 3Affordable Health Choices Act Is an Excellent Step Toward Health Care Reform 51832 1Affordable Health Choices Act Is an Excellent Step Toward Health Care Reform 51832 2